WCN26-6551 PCSK9 Inhibition Attenuates Renal Lipotoxicity by Activating AMPK in Diabetic Kidney Disease

Key Points

• The study aims to evaluate the effects of PCSK9 inhibition on renal lipotoxicity and its mechanism through AMPK activation in diabetic kidney disease.
• Panel discussions were conducted to gather expert opinions.
• Focus on treatment strategies for adults with chronic kidney disease (CKD) and type 2 diabetes (T2D).
• Assess the role of SGLT2 inhibitors and GLP-1 receptor agonists in treatment.
• Panelists recommended SGLT2 inhibitors as foundational therapy.
• GLP-1 receptor agonists were endorsed for patients with obesity and metabolic risks.
• Early kidney protection was emphasized as a treatment goal.